里昂发表研究报告，对中资医药股最新评级及目标价如下： 股份│投资评级│目标价(港元) 相关内容《大行》大摩更新石药(01093.HK)风险回报评估 目标价下调至10.4元中生制药(01177.HK) +0.080 (+1.233%) 沽空 $6.05千万; 比率 17.189% │买入│14.17元石药(01093.HK) +0.190 (+2.372%) 沽空 $5.00亿; 比率 30.456% │买入│23.37元三生制药(01530.HK) +0.760 (+2.992%) 沽空 $1.23亿; 比率 18.320% │买入│17.43元复星医药(02196.HK) +0.460 (+2.231%) 沽空 $7.29百万; 比率 7.614% │跑输大市│23.53元翰森制药(03692.HK) -0.460 (-1.181%) 沽空 $4.43千万; 比率 15.155% │跑赢大市│30.77元中国同辐(01763.HK) +0.320 (+1.546%) │买入│26.78元百济神州(06160.HK) +1.100 (+0.597%) 沽空 $7.45千万; 比率 12.008% │买入│144.04元华领医药(02552.HK) +0.090 (+2.961%) 沽空 $52.29万; 比率 5.946% │买入│10.34元药明生物(02269.HK) +1.440 (+4.401%) 沽空 $1.65亿; 比率 11.009% │买入│102.62->139.69元药明康德(02359.HK) +1.500 (+1.466%) 沽空 $4.04亿; 比率 33.076% │买入│115.63->142.37元方达控股(01521.HK) -0.010 (-0.980%) │跑赢大市->买入│5.97元康龙化成(03759.HK) +0.880 (+4.128%) 沽空 $9.75百万; 比率 10.275% │买入│53.69->68.25元国药(01099.HK) +0.060 (+0.303%) 沽空 $1.80千万; 比率 17.626% │买入│38.69元华润医药(03320.HK) +0.030 (+0.661%) 沽空 $7.58百万; 比率 14.781% │买入│14.21元上海医药(02607.HK) -0.030 (-0.253%) 沽空 $14.95万; 比率 0.374% │买入│24.04元锦欣生殖(01951.HK) +0.030 (+1.210%) 沽空 $7.08百万; 比率 22.719% │跑赢大市->买入│15.37元 (sw/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-19 16:25。)